SCHEMBL2162691

SCHEMBL2162691

OC1CN(c2ccn3c(n2)nc2ccccc23)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
POLB P06746 2/20 0.40
PDE10A Q9Y233 4/20 0.39
MAPK8 P45983 1/20 0.38
NPSR1 Q6W5P4 1/20 0.36
PTPN2 P17706 1/20 0.36
PTPN1 P18031 1/20 0.36
HTR3E A5X5Y0 1/20 0.36
HTR3B O95264 1/20 0.36
HTR3A P46098 1/20 0.36
HTR3D Q70Z44 1/20 0.36
HTR3C Q8WXA8 1/20 0.36
KDM4E B2RXH2 2/20 0.34
PRKDC P78527 1/20 0.34
OPRM1 P35372 2/20 0.34
OPRD1 P41143 2/20 0.34
OPRK1 P41145 2/20 0.34
OGFRL1 Q5TC84 2/20 0.34
LCK P06239 1/20 0.34
GLA P06280 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2163727 0.86 SMPD3 (0.43) PDE10AMAPK8HTR3EHTR3BHTR3A
SCHEMBL17274183 0.86 SMPD3 (0.41) ALDH1A1POLBPDE10ANPSR1PTPN2
SCHEMBL23048328 0.86 SMPD3 (0.41) ALDH1A1POLBPDE10ANPSR1PTPN2
SCHEMBL12324150 0.86 POLB (0.40) ALDH1A1POLBPDE10ANPSR1PTPN2
SCHEMBL25801350 0.86 SMPD3 (0.41) ALDH1A1POLBPDE10ANPSR1PTPN2
SCHEMBL18053572 0.83 POLB (0.43) ALDH1A1POLBPDE10ANPSR1PTPN2
SCHEMBL20128584 0.83 POLB (0.38) ALDH1A1POLBPDE10ANPSR1PTPN2
SCHEMBL17274204 0.81 HTR3E (0.36) ALDH1A1POLBPDE10ANPSR1HTR3E
SCHEMBL25801001 0.81 HTR3E (0.36) ALDH1A1POLBPDE10ANPSR1HTR3E
SCHEMBL23964777 0.80 POLB (0.39) POLBPTPN2PTPN1HTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2550255-B1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS LILLY CO ELI (US) 2016-04-27 EP disclosed
EP-2550255-B1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS LILLY CO ELI (US) 2016-04-27 EP disclosed
EP-2550255-A1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS Siemens Medical Solutions USA, Inc. (US) 2013-01-30 EP disclosed
WO-2011119565-A1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-09-29 WO disclosed
WO-2011119565-A1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-09-29 WO disclosed
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-07-28 US disclosed
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-07-28 US disclosed
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders MAPT, APP, PSEN1 ALDH1A1 3926/4885POLB 2199/4885PDE10A 757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.